Patent · US Active

HDAC 6 inhibitor-based methods for treating cancer

US9539272B2 · kind B2 · utility

0Cited by

0References

14Claims

0Family size

Assignee

Sloan Kettering Institute for Cancer Research · US

Inventors

Paul A. Marks · Washington, US
Weisheng Xu · Elmont, US
Mandana Namdar · London, GB

Key dates

Filing date	Jul 2, 2010
Grant date	Jan 10, 2017
Priority date	—
Expiry date	Nov 20, 2033

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention provides methods for treating a subject afflicted with cancer, comprising concurrently administering (i) an HDAC 6-selective inhibitor and (ii) a suitable cytotoxic agent such as SAHA, doxorubicin or etoposide. This invention also provides methods for inducing the death of a transformed cell such as a cancer cell, comprising concurrently contacting the cell with (i) an HDAC 6-selective inhibitor and (ii) a suitable cytotoxic agent such as SAHA, doxorubicin or etoposide.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.